Journal of Adolescent Health
Volume 36, Issue 1 , Pages 92-93 , January 2005

Suicidality in adolescents being treated with antidepressant medications and the black box label: Position paper of the Society for Adolescent Medicine

  • James Lock, M.D., Ph.D.

      Affiliations

    • Department of Psychiatry and Behavioral Medicine, Stanford University School of Medicine, Stanford, California, USA
    • ,
  • Leslie R. Walker, M.D. (FSAM)

      Affiliations

    • Department of Pediatrics, Adolescent Medicine, Georgetown University Hospital, Washington, DC, USA
    • ,
  • Vaughn I. Rickert, Psy.D. (FSAM)

      Affiliations

    • Heilbrunn Department of Population and Family Health, Mailman School of Public Health at Columbia University, New York, New York, USA
    • ,
  • Debra K. Katzman, M.D. (FSAM)

      Affiliations

    • Division of Adolescent Medicine, Department of Paediatrics, The Eating Disorder Program, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada

References 

  1. Brent DA . Antidepressants and pediatric depression-the risk of doing nothing . N Engl J Med . 2004;351:1598–1601
  2. Lewinsohn PM , Hops H , Roberts RE , Seeley JR , Andrews JA . Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students . J Abnorm Psychol . 1993;102:133–144
  3. Kovacs M . Presentation and course of major depressive disorder during childhood and later years of the life span . J Am Acad Child Adolesc Psychiatry . 1996;35:705–715
  4. Lewinsohn PM , Rohde P , Seeley JR , Klein DN , Gotlib IH . Natural course of adolescent major depressive disorder in a community sample (predictors of recurrence in young adults) . Am J Psychiatry . 2000;157:1584–1591
  5. National Institute of Mental Health . Depression in children and adolescents (a fact sheet for physicians) . 2004; www.nimh.nih.gov/publicat/depchildresfact.cfm. Accessed March 8
  6. Brent DA . Assessment and treatment of the youthful suicidal patient . Ann N Y Acad Sci . 2001;932:106–128
  7. March J , Silva S , Petrycki S , et al.   Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression (Treatment for Adolescents with Depression Study (TADS) randomized controlled trial) . JAMA . 2004;292:807–820
  8. Emslie GJ , Rush AJ , Weinberg WA , et al.   A double-blind, randomized placebo-controlled trial of fluoxetine in children and adolescents with depression . Arch Gen Psychiatry . 1997;54:1031–1037
  9. Emslie GJ , Heiligenstein JH , Wagner KD , et al.   Fluoxetine treatment for prevention of relapse of depression in children and adolescents (a double-blind, placebo-controlled study) . J Am Acad Child Adolesc Psychiatry . 2002;41:1205–1215
  10. FDA launches a multi-pronged strategy to strengthen safeguards for children treatment with antidepressants medications, U.S. Food and Drug Administration, FDA News, October 15, 2004. www.fda.gov/bbs/topics/news/2004/NEW01124.html Accessed November 11, 2004.
  11. Newman TB . A black-box warning for antidepressants in children? . N Engl J Med . 2004;351:1595–1598
  12. Brent DA , Birmaher B . Adolescent depression . N Engl J Med . 2000;347:667–671
  13. Zametkin AJ , Alter MR , Yemini T . Suicide in teenagers (assessment, management, and prevention) . JAMA . 2001;286:3120–3125
  14. Sarles RM . Joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee. Academy of Child and Adolescent Psychiatry . 2004; http://www.aacap.org/Announcements/AACAP_Comment.html. Accessed September 28

 The guidance in this Position Paper does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

PII: S1054-139X(04)00394-5

doi: 10.1016/j.jadohealth.2004.11.125

Journal of Adolescent Health
Volume 36, Issue 1 , Pages 92-93 , January 2005

Article Tools